Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 9c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $269.10 +2.64%
EPS Growth %: +25.6%
Financial Fact:
Total other income (expense), net: -4.26M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +25.6%
Financial Fact:
Total other income (expense), net: -4.26M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q1 EPS of $0.07, $0.09 better than the analyst estimate of ($0.02). Loss from continuing ops was ($0.03). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $8.02 million.
Ligand Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Ligand Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
- GA Advisory & Valuation Services Launches Dedicated Financial Due Diligence (QoE) Practice and Appoints Ryan Irby as Managing Director
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
